Resources for Health Systems, Health Care Providers, and Researchers
Find resources for health systems, health care providers, and researchers on dementia risk reduction, detection and diagnosis, treatment and care, ALZ-NET operations, and more.
Prevention and risk reduction
This section contains resources to support public health education.
- Risk Reduction
Website | Developed by the Alzheimer’s Association. - Modifiable Risk Factors for Dementia Microlearning Series
Video | Developed by the Alzheimer’s Association. - Epidemiology of Dementia and Cognitive Decline in Diverse Populations
Video | Developed by the Alzheimer’s Association.
Assessment, detection, and diagnosis
This section contains resources specific to the assessment tools and diagnostics that could support clinicians. There are a variety of tools and tests available, ALZ-NET will require some specific assessments to be documented and resources for these are denoted below.
- Dementia Diagnosis
Website | Developed by the Alzheimer’s Association.
Cognitive and functional assessments
- Cognitive Screening and Assessment
Website | Developed by the Alzheimer’s Association. - Montreal Cognitive Assessment (MoCA) – Required Assessment for ALZ-NET
Website | Developed by MoCA Cognition. - Mini-Mental State Exam (MMSE) – Required Assessment for ALZ-NET
Website | Developed by Psychological Assessment Resources. - Functional Activities Questionnaire (FAQ) – Required Assessment for ALZ-NET
PDF | Developed by The Hartford Institute for Geriatric Nursing, New York University, College of Nursing, and the Alzheimer’s Association. - AD8 Screening Assessment – Optional Assessment for ALZ-NET
PDF | Developed by the Alzheimer’s Disease Research Center, Washington University, St. Louis, Missouri. All Rights Reserved. - The Neuropsychiatric Inventory Questionnaire (NPI-Q) – Optional Assessment for ALZ-NET
PDF | Developed by Jeffrey Cummings, MD. ALZ-NET is providing the NPI-Q to you for your clinical use. Any commercial application of the instrument requires separate permission. J Cummings 1995; All Rights Reserved.
Imaging
- ALZ-NET Imaging Education and Resources
Website | Developed by the American College of Radiology.
Biofluid analysis
Cerebrospinal Fluid
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease
Publication - Alzheimer’s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau
Publication
Blood and Plasma
- Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease
Publication - Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease–related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group
Publication
Genetic testing
- Alzheimer’s Disease Treatment Clinic: Genetic Testing
PDF | Shared with permission from Mayo Clinic Rochester, Department of Neurology.
Treatment and comprehensive care
This section contains resources focused on treatment delivery, management, and dementia memory care.
FDA-approved amyloid targeting treatments tracked in ALZ-NET
- Patient-Focused Decision Guide When Considering Infused Amyloid Reducing Drugs for Alzheimer’s Disease
PDF | Shared with permission by a subcommittee of the Alzheimer’s Clinical Trials Consortium (ACTC) Research Participant Advisory Board. - Alzheimer’s Disease Treatment Clinic - overview
PDF | Shared with permission from Mayo Clinic Rochester, Department of Neurology. - MedTraker
Website | Shared with permission from Abington Neurological Associates. All Rights Reserved. - Infusion Candidates Template
Excel Template | Shared with permission from Washington University in St. Louis.
Aduhelm® (aducanumab)
Aducanumab is being discontinued. Patients who are now receiving it by prescription will have it available to them until Nov. 1, 2024.
- Aduhelm® (aducanumab) – United States Prescribing Information (USPI) and MedGuide
PDF | Developed by the manufacturer and U.S. Food and Drug Administration (FDA). - Aducanumab: Appropriate Use Recommendations Update
Publication
Leqembi® (lecanemab)
- Leqembi® (lecanemab) – United States Prescribing Information (USPI) and MedGuide
PDF | Developed by the manufacturer and U.S. Food and Drug Administration (FDA). - Lecanemab Appropriate Use Recommendations
Publication - Leqembi® (lecanemab) – Clinician Toolkit
PDF | Developed the Alzheimer’s Association. - Lecanemab: Frequently Asked Questions
PDF | Shared with permission from Mayo Clinic Rochester, Department of Neurology. - A Patient’s Journey through the Alzheimer’s Disease Treatment Clinic - Lecanemab
PDF | Shared with permission from Mayo Clinic Rochester, Department of Neurology.
FDA-approved neuropsychiatric treatments tracked in ALZ-NET
Rexulti® (brexpiprazole)
- Rexulti® (brexpiprazole) – United States Prescribing Information (USPI) and MedGuide
PDF | Developed by the manufacturer and the U.S. Food and Drug Administration (FDA).
Comprehensive care
- Alzheimer’s and Dementia Care ECHO® Program for Health Systems and Medical Professionals
Website | Developed by the Alzheimer’s Association. - Alzheimer’s Association Dementia Care Practice Recommendations
PDF | Developed by the Alzheimer’s Association. - Medical Management and Patient Care
Website | Developed by the Alzheimer’s Association. - Clinical Trials Recruiting
Website | Developed by the Alzheimer’s Association.
Person-centered care and communication
This section contains resources focused on the journey map of patient experience.
- Dementia Care Planning Visit
Website | Developed by the Alzheimer’s Association.
Medicare and billing
- ALZ-NET Medicare and Billing Resources
Website | Developed by the American College of Radiology.
ALZ-NET operations
All resources related to ALZ-NET operations are managed by the American College of Radiology.
Additional Alzheimer’s Association resources
Browse information, tools and resources for those working in the field of Alzheimer’s and dementia care, including for health systems, medical and health care professionals, professional care providers and public health professionals.
For any additional resources, alz.org/professionals
- Clinical education training: The Association offers a number of online Alzheimer’s and dementia courses for scientists, clinicians, physicians, and dementia professionals.
- Research webinars and training: Join the Alzheimer’s Association and ISTAART for a series of webinars that share the latest advances in Alzheimer's and dementia research and career development strategies.
- Public health training: The Association is your source for online courses about public health and dementia for public health students, educators, and professionals.
- Future scientific meetings: Attend an upcoming in-person or virtual conference to learn and network within the dementia science community – one of the many year-round opportunities offered by the Alzheimer’s Association.
- ISTAART: The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) is an inclusive global network of scientists, clinicians, and dementia professionals. Members of this professional organization share common goals: the pursuit of knowledge, collaboration, and breakthroughs to advance the research and treatment of Alzheimer’s disease and other dementias.
- ISTAART Voices: ISTAART Voices is a new podcast that navigates the intricate world of dementia research, practice, and treatment. Join us as we explore the latest research in conversation with study authors from the Alzheimer’s & Dementia® journal family. You can earn Continuing Medical Education (CME) and Continuing Education (CE) at no cost when you listen to this podcast.
- Funding opportunities: The Alzheimer’s Association is the world’s largest non-profit funder of Alzheimer’s and dementia science. The Alzheimer’s Association International Research Grant Program (IRGP) supports Alzheimer’s and dementia researchers at every professional stage and includes categories aimed at addressing research gaps.